John Arthur Deedrick Net Worth

The estimated Net Worth of John Arthur Deedrick is at least $17.5 Tausend dollars as of 1 July 2016. John Deedrick owns over 11,764 units of Xtant Medical Inc stock worth over $17,457 and over the last 8 years John sold XTNT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Deedrick XTNT stock SEC Form 4 insiders trading

John has made over 2 trades of the Xtant Medical Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently John exercised 11,764 units of XTNT stock worth $7,235 on 1 July 2016.

The largest trade John's ever made was exercising 11,764 units of Xtant Medical Inc stock on 1 July 2016 worth over $7,235. On average, John trades about 7,843 units every 0 days since 2016. As of 1 July 2016 John still owns at least 28,385 units of Xtant Medical Inc stock.

You can see the complete history of John Deedrick stock trades at the bottom of the page.

What's John Deedrick's mailing address?

John's mailing address filed with the SEC is Cruiser Lane, Belgrade, Gallatin County, Montana, 59714, United States.

Insiders trading at Xtant Medical Inc

Over the last 9 years, insiders at Xtant Medical Inc have traded over $104,833 worth of Xtant Medical Inc stock and bought 5,164,288 units worth $21,623,047 . The most active insiders traders include Stavros G. Vizirgianakis, Advisors Llc Orbimed und Matthew Rizzo. On average, Xtant Medical Inc executives and independent directors trade stock every 117 days with the average trade being worth of $134,096. The most recent stock trade was executed by Kevin D Brandt on 17 November 2023, trading 41,670 units of XTNT stock currently worth $50,004.

What does Xtant Medical Inc do?

xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.

Complete history of John Deedrick stock trades at Xtant Medical Inc

Xtant Medical Inc executives and stock owners

Xtant Medical Inc executives and other stock owners filed with the SEC include:

• Sean E. Browne,
  Pres, CEO & Director
• Kevin D. Brandt,
  Sr. VP & Chief Commercial Officer
• Darrel Holmes,
  Chief Operating Officer
• Gregory Juda,
  Chief Scientific Officer
• Rich Cockrell,
  IR Contact Officer
• Matthew Rizzo,
  Director
• Jeffrey Peters,
  Director
• Robert McNamara,
  Director
• Michael Eggenberg,
  Director
• John Bakewell,
  Director
• Kevin Brandt,
  Senior Vice President, Chief Commercial Officer
• Greg Jensen,
  Chief Financial Officer, Vice President - Finance
• Sean Browne,
  President, Chief Executive Officer, Director
• Kevin M. O'Dare,
  VP of Sales - Eastern US
• Catherine Lundy,
  VP of HR
• Scott Neils,
  Interim CFO & Controller
• Scott C Neils,
  Chief Financial Officer
• Jonn R. Beeson,
  Director
• Eric Bernard Timko,
  Director
• Kent L Swanson,
  Director
• John Arthur Deedrick,
  Director
• David Louis Kirschman,
  EVP & Chief Scientific Officer
• Daniel S Goldberger,
  Chief Executive Officer
• Rudy A Mazzocchi,
  Director
• Jon M. Wickwire,
  
• David Goodman,
  
• Paul Buckman,
  Director
• Michael A Lopach,
  Director
• Advisors Llc Orbimed,
  Director
• Kathie J. Lenzen,
  Chief Financial Officer
• Carl O'connell,
  Chief Executive Officer
• Michael Mainelli,
  Interim CEO
• Ronald G. Berlin,
  VP & Chief Operations Officer
• Advisors Llc Orbimed Rof Ii...,
  
• Lori D Mitchell Keller,
  Director
• Mark A. Schallenberger,
  Chief Operations Officer
• Stavros G. Vizirgianakis,
  Director